Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO, shares final OS data from the phase 3 ALEX study in ALK-positive NSCLC.
Tony S. K. Mok, MD, BMSc, FRCPC, FASCO
Advertisement
Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, is chairman of the Department of Clinical Oncology and the Li Shu Fan Professor of Clinical Oncology at the Chinese University of Hong Kong
Articles by Tony S. K. Mok, MD, BMSc, FRCPC, FASCO
Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, discusses first-line treatment decision-making for patients with BRAF-mutant non–small cell lung cancer.
Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, previews discussion topics for the upcoming webinar hosted by OncLive on the novel coronavirus 2019 (COVID-19).
Advertisement
Latest Updated Articles
Dr Mok on Choosing Between First-Line Therapies for BRAF-Mutant NSCLCPublished: July 25th 2025 | Updated:
Dr. Mok Previews Discussion Topics for the Upcoming COVID-19 WebinarPublished: April 4th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5